What is the major neurotoxic effect of vincristine in pediatric patients and how should it be assessed?

• A. Peripheral neuropathy (sensory/motor) with possible numbness, weakness, and paresthesias; assess gait, reflexes, sensation, and monitor for constipation.
• B. Nephrotoxicity with elevated creatinine.
• C. Ototoxicity leading to hearing loss.
• D. Cardiotoxicity presenting as chest pain.

Answer: (D)

The main point is that vincristine most notably causes peripheral neuropathy in children, affecting both sensory and motor nerves. This neurotoxicity shows up as numbness, tingling, or pain in the hands and feet, weakness, difficulty with walking or fine motor tasks, and reduced reflexes. Autonomic nerves can also be involved, leading to constipation or other GI symptoms; constipation is a common early sign and should prompt proactive management.

To assess this, perform regular, systematic neuro exams before each cycle: ask about numbness or tingling, test sensation (light touch and vibration) in the feet and hands, evaluate motor strength in major muscle groups, check reflexes, and observe gait and the ability to perform tasks like buttoning or handwriting. Also monitor bowel function and look for new or worsening constipation, since autonomic neuropathy can signal evolving neurotoxicity.

Management hinges on severity. If neuropathy is mild to moderate, close monitoring may allow continuation with caution; if it becomes more severe, hold or reduce vincristine and reassess after improvement. This approach reflects the emphasis on nerve function when guiding therapy. Other listed toxicities—nephrotoxicity, ototoxicity, and cardiotoxicity—are not the primary neurotoxic effects of vincristine, though a broader review of potential adverse effects is still important in comprehensive care.